FIELD: medicine.
SUBSTANCE: for treatment of a proliferative disease characterized with BRAFkinase mutation, a BRAF inhibitor of formula
is administered intermittently, comprising BRAF inhibitor administration for 1, 2, 3, 4, 5, or 6 weeks followed by a period of 1, 2, 3 4, 5, or 6 weeks without treatment. Application of the BRAF inhibitor of formula II is also proposed for manufacture of a medicament for proliferative disease treatment.
EFFECT: increased efficiency of treatment due to delay or prevention of resistance against the BRAF inhibitor.
7 cl, 1 dwg, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMBINATION THERAPY | 2018 |
|
RU2815400C2 |
| PHARMACEUTICAL COMBINATIONS OF CDK4/6 INHIBITOR AND B-Raf INHIBITOR | 2013 |
|
RU2685250C2 |
| THERAPEUTIC COMBINATIONS CONTAINING RAF INHIBITOR AND ERK INHIBITOR | 2017 |
|
RU2774612C2 |
| BRAF KINASE INHIBITOR N-(3-(5-(4-CHLOROPHENYL)-1H-PYRAZOLO[3,4-B]PYRIDIN-3-CARBONIL)-2,4-DIFLUOROPHENYL)PROPANE-1-SULFONAMIDE | 2018 |
|
RU2687107C1 |
| N-(3-(5-(4-CHLOROPHENYL)-1N-PYRAZOLO[3,4-B]PYRIDINE-3-CARBONYL)-2,4-DIFLUOROPHENYL)PROPANE-1-SULPHONAMIDE CRYSTALLINE FORM, ACTIVE COMPONENT, PHARMACEUTICAL COMPOSITION AND MEDICINE | 2018 |
|
RU2678455C1 |
| PHARMACEUTICAL COMBINATIONS | 2017 |
|
RU2759669C2 |
| METHOD FOR ADJUVANT THERAPY OF CANCER | 2013 |
|
RU2640180C2 |
| DETERMINATION OF CELL SENSITIVITY TO TREATMENT WITH B-Raf INHIBITOR BY DETECTION OF K-ras MUTATION AND LEVELS OF RTK EXPRESSION | 2010 |
|
RU2553379C2 |
| COMPOUND FOR TREATING CANCER | 2014 |
|
RU2708247C2 |
| COMBINATION OF (A) PHOSPHOINOSITIDE-3-KINASE INHIBITOR AND (B) Ras/Raf/Mek PATHAWAY MODULATOR | 2009 |
|
RU2508110C2 |
